scholarly journals Disproportionate Body Composition and Neonatal Outcome in Offspring of Mothers With and Without Gestational Diabetes Mellitus

Diabetes Care ◽  
2013 ◽  
Vol 36 (11) ◽  
pp. 3543-3548 ◽  
Author(s):  
M. Persson ◽  
H. Fadl ◽  
U. Hanson ◽  
D. Pasupathy
Keyword(s):  
Diabetes Mellitus ◽  
Body Composition ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Neonatal Outcome

scholarly journals Ghrelin in Serum and Urine of Post-Partum Women with Gestational Diabetes Mellitus

2018 ◽  
Vol 19 (10) ◽  
pp. 3001 ◽  
Author(s):  
Żaneta Kimber-Trojnar ◽  
Jolanta Patro-Małysza ◽  
Katarzyna Skórzyńska-Dziduszko ◽  
Jan Oleszczuk ◽  
Marcin Trojnar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Composition ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Post Partum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Hydration Status ◽  
Increased Risk ◽  
Serum Ghrelin ◽  
Serum And Urine

Women with a previous history of gestational diabetes mellitus (GDM) have a significantly increased risk of developing type 2 diabetes, obesity, and cardiovascular diseases in the future. The aim of the study was to evaluate ghrelin concentrations in serum and urine in the GDM group in the early post-partum period, with reference to laboratory results, body composition, and hydration status. The study subjects were divided into two groups, that is, 28 healthy controls and 26 patients with diagnosed GDM. The maternal body composition and hydration status were evaluated by the bioelectrical impedance analysis (BIA) method. The concentrations of ghrelin in the maternal serum and urine were determined via enzyme-linked immunosorbent assay (ELISA). The laboratory and BIA results of the mothers with GDM were different from those without GDM. Urine ghrelin positively correlated with serum ghrelin and high-density lipoprotein cholesterol (HDL) levels in healthy mothers. There were direct correlations between urine ghrelin and HDL as well as triglycerides levels in the GDM group. Neither the lean tissue index nor body cell mass index were related to the serum ghrelin concentrations in this group. Only the urine ghrelin of healthy mothers correlated with the fat tissue index. Our results draw attention to urine as an easily available and appropriable biological material for further studies.

scholarly journals Response to Comment on: Au et al. Body Composition Is Normal in Term Infants Born to Mothers With Well-Controlled Gestational Diabetes Mellitus. Diabetes Care 2013;36:562–564

Diabetes Care ◽  
2013 ◽  
Vol 36 (9) ◽  
pp. e164-e164
Author(s):  
Cheryl P. Au ◽  
Camille H. Raynes-Greenow ◽  
Robin M. Turner ◽  
Angela E. Carberry ◽  
Heather E. Jeffery
Keyword(s):  
Diabetes Mellitus ◽  
Body Composition ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Diabetes Care ◽  
Term Infants

Neonatal Outcome and Its Correlation with Hemoglobin A1c in Gestational Diabetes Mellitus

2017 ◽  
Vol 9 (3) ◽  
pp. 216-220
Author(s):  
Savita Somalwar ◽  
Preksha Jain ◽  
Pritesh Jain
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Neonatal Intensive Care ◽  
Hemoglobin A1c ◽  
Neonatal Outcome ◽  
Statistical Tests ◽  
Neonatal Morbidity ◽  
P Value ◽  
Neonatal Deaths

ABSTRACT Aim To determine neonatal outcome in women with gestational diabetes mellitus (GDM) diagnosed using Diabetes in Pregnancy Study Group of India (DIPSI) recommended method. Materials and methods Out of 487 antenatal women, 52 were diagnosed with GDM using DIPSI test. All women were followed up until delivery and evaluated for neonatal outcome and managed accordingly. The appropriate statistical tests for various variables were applied by using Epi Info 7 software and evaluated at the level below than 5%. Results Apgar score of <6 at 5 minutes was found in 10 (20%) neonates of GDM mothers as compared with 18 (4.1%) in non-GDM group (p-value of 0.00001). Respiratory distress was present in 19 (38%) neonates in GDM group, while it was 48 (11.1%) in non-GDM group (p-value of 0.00002). Association of GDM and hyperbilirubinemia was nonsignificant in 2 (4%) neonates among GDM group, while it was 6 (1.4%) in non-GDM group. Hypoglycemia was 5 (10%) in GDM group, while 3 (0.7%) in non-GDM group (p-value of <0.0003). A total of 3 (6%) among GDM group had hypocalcemia, while 3 (0.7%) had hypocalcemia in non-GDM group (p-value of 0.02). The neonatal intensive care unit admissions were 29 (58%) in GDM group, while it was 96 (22.1%) neonates belonging to non-GDM group (p-value of 0.00001). No neonatal deaths were reported in GDM group, while there were 2 (0.5%) in non-GDM group. Anomalies were found in 6 (11.5%) in GDM group as compared with 5 (1.1%) in non-GDM (p-value of 0.00001). About 44.2% women with GDM had hemoglobin (Hb)A1c levels between 6 and 6.9%. Among GDM women, 4 (7.7%) had pregnancy losses as compared with 7 (1.6%) in non-GDM group. Conclusion The GDM is associated with significant fetal and neonatal morbidity; hence, preconceptional counseling, early diagnosis, and proper treatment are recommended. Clinical significance Preconceptional correction of HbA1c is also recommended based on risk of anomalies in fetus of GDM mother. How to cite this article Jain P, Somalwar S, Jain P. Neonatal Outcome and Its Correlation with Hemoglobin A1c in Gestational Diabetes Mellitus. J South Asian Feder Obst Gynae 2017;9(3):216-220.

scholarly journals The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Rachel K. Harrison ◽  
Meredith Cruz ◽  
Ashley Wong ◽  
Caroline Davitt ◽  
Anna Palatnik
Keyword(s):  
Diabetes Mellitus ◽  
Preterm Birth ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Gestational Age ◽  
Pregnancy Outcomes ◽  
Neonatal Outcome ◽  
Group 2 ◽  
Nicu Admission ◽  
Group 1

Abstract Background The decision to initiate pharmacotherapy is integral in the care for pregnant women with gestational diabetes mellitus (GDM). We sought to compare pregnancy outcomes between two threshold percentages of elevated glucose values prior to initiation of pharmacotherapy for GDM. We hypothesized that a lower threshold at pharmacotherapy initiation will be associated with lower rates of adverse perinatal outcomes. Methods This was a retrospective cohort study of women with GDM delivering in a single tertiary care center. Pregnancy outcomes were compared using bivariable and multivariable analyses between women who started pharmacotherapy (insulin or oral hypoglycemic agent) after a failed trial of dietary modifications at two different ranges of elevated capillary blood glucose (CBG) values: Group 1 when 20–39% CBG values were above goal; Group 2 when ≥40% CBG values were above goal. The primary outcome was a composite GDM-associated neonatal adverse outcome that included: macrosomia, large for gestational age (LGA), shoulder dystocia, hypoglycemia, hyperbilirubinemia requiring phototherapy, respiratory distress syndrome, stillbirth, and neonatal demise. Secondary outcomes included cesarean delivery, preterm birth (< 37 weeks), neonatal intensive care unit (NICU) admission, and small for gestational age (SGA). Results A total of 417 women were included in the study. In univariable analysis, the composite neonatal outcome was statistically significantly higher in Group 2 compared to Group 1 (47.9% vs. 31.4%, p = 0.001). In addition, rates of preterm birth (15.7% vs 7.4%, p = 0.011), NICU admission (11.7% vs 4.0%, p = 0.006), and LGA (21.2% vs 9.1% p = 0.001) were higher in Group 2. In contrast, higher rates of SGA were noted in Group 1 (8.0% vs. 2.9%, p = 0.019). There was no difference in cesarean section rates. These findings persisted in multivariable analysis after adjusting for confounding factors (composite neonatal outcome aOR = 0.50, 95%CI [0.31–0.78]). Conclusions Initiation of pharmacotherapy for GDM when 20–39% of CBG values are above goal, compared to ≥40%, was associated with decreased rates of adverse neonatal outcomes attributable to GDM. This was accompanied by higher rates of SGA among women receiving pharmacotherapy at the lower threshold. Additional studies are required to identify the optimal threshold of abnormal CBG values to initiate pharmacotherapy for GDM.

Sign in / Sign up

Export Citation Format

Share Document